8-K - IMDX - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): December 14, 2021

OncocyteCorporation

(Exact name of registrant as specified in its charter)

California	1-37648	27-1041563
(State<br> or other jurisdiction	(Commission	(IRS<br> Employer
of<br> incorporation)	File<br> Number)	Identification<br> No.)

15Cushing

Irvine,California 92618

(Address of principal executive offices)

(949)409-7600

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common<br> Stock, no par value	OCX	The<br> Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Forward-LookingStatements

Anystatements that are not historical fact (including, but not limited to statements that contain words such as “may,” “will,”“believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”)should be considered to be forward-looking statements. Factors that could cause actual results to differ materially from the resultsanticipated in these forward-looking statements are contained under the heading “Risk Factors” in Oncocyte Corporation’sAnnual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) and in other filings that Oncocyte maymake with the SEC. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made,and the facts and assumptions underlying these statements may change. Except as required by law, Oncocyte disclaims any intent or obligationto update these forward-looking statements.

Referencesto “Oncocyte,” “we,” “us,” and “our” are references to Oncocyte Corporation.

Theinformation in Item 7.01 and the accompanying Exhibit 99.1 shall be deemed “furnished” and not “filed” underSection 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilityof that section, and shall not be incorporated by reference into any filings made by Oncocyte under the Securities Act of 1933, as amended,or the Exchange Act except as may be expressly set forth by specific reference in such filing.

Item7.01 - Regulation FD Disclosure

Exhibit 99.1 furnished with this Report consists of slides presenting information on product development, development plans, and related matters presented to attendees of Oncocyte’s Investor Day program on December 14, 2021.

Item9.01 Financial Statements and Exhibits.

Exhibit<br> Number	Description
99.1	Slide presentation
104	Cover<br> Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ONCOCYTE CORPORATION
Date:<br> December 14, 2021	By:	/s/ Mitchell Levine
		Mitchell<br> Levine
		Chief<br> Financial Officer

Exhibit99.1